NIH-funded research R21 grant

Investigating how specific proteins affect myelin formation in the brain

Official title: A synaptogenic adhesion code for myelin specificity

Funded at University of Colorado Denver · NIH-11112207 · Data updated 2026-11-12

This study is looking at how certain proteins might affect the protective covering around nerve fibers in the brain, which is important for people with autism, to see if changes in these proteins could help explain some of the brain differences seen in autism.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Colorado Denver
NIH-funded
Lab location1 site (Aurora, UNITED STATES)
Project startJune 1, 2025
Project endMay 31, 2027
Funding year2025
Award (this year)$429,000
NIH project number1R21MH140123-01
Project IDNIH-11112207 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with autism spectrum disorder or those exhibiting autism-like symptoms.

Less likely to help

Patients without autism spectrum disorder or related neuropsychiatric conditions may not benefit from this research.

What this research studies

This research explores the role of certain proteins in the formation and maintenance of myelin, which is crucial for proper brain function. By examining genetic variants associated with autism spectrum disorder (ASD), the study aims to understand how these variants may disrupt the interaction between myelin and neuronal axons. The researchers will focus on three specific synaptic adhesion molecules to determine their influence on myelin development. This could provide insights into the underlying mechanisms of white matter abnormalities in neuropsychiatric disorders.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies for improving myelin health in individuals with autism spectrum disorder.

How similar studies have gone: While the specific approach of investigating synaptic adhesion molecules in relation to myelin is novel, previous research has shown that understanding genetic variants can lead to breakthroughs in treating neuropsychiatric disorders.

Where this research is happening

  • University of Colorado Denver
    Aurora, United States
    Active

Researchers

  • Principal investigator: Appel, Bruce H — University of Colorado Denver
  • Study coordinator: Appel, Bruce H

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.